National White Collar Crime Center

This paper discusses the application of Brain-Computer Interface (BCI) technologies in improving communication abilities for Locked-In Syndrome or Pseudocoma Patients. Pseudocoma is a condition where individuals are conscious but unable to speak or move due to a paralytic situation. BCI technology allows direct communication between the external devices and the brain, allowing patients to control devices using their brain signals. This paper focuses on some possible solutions based on motor imagery signals generated by pseudocoma patient which are either used as single or double-triggering signals enabling them to communicate, control their environment, and potentially regain some independence. The findings of this research discuss the possibilities of enhancing the lives of patients with Pseudocoma by using motor imagery signals blended with AI-based software solutions. Also, it shows an application architecture that can be integrated with BCI systems to help pseudocoma patients express themselves and interact with others. The study also highlights the neuro-technology which uses neural interfaces to read or write information into the CNS (Central Nervous System) which can be a significant potential of BCI technology in empowering pseudocoma patients to communicate effectively and improve their overall well-being.

Background: Monoclonal antibodies against IL-1β decrease inflammation, improve insulin secretion and glycaemia, and reduce residual CV risk, but must be injected and are associated with higher incidence of fatal infection. There remains an unmet need for an oral treatment for T2D patients at risk for cardiometabolic complications to safely reduce IL-1β-mediated inflammation chronically&with low risk of immunosuppression. In an initial dose-range finding study in heart failure patients with T2D, we reported evidence of anti-hyperglycaemic efficacy and improvement in LVEF with dapansutrile an oral specific inhibitor of the NLRP3 inflammasome. Objectives: To investigate the potential of preventing the transition to organ complications, The EU funded consortium INTERCEPT-T2D in collaboration with US based biotech Olatec Therapeutics has launched a clinical trial of anti-inflammatory therapy with dapansutrile targeting T2D patients with low-grade inflammation. Methods: Dapansutrile in Diabetes and Complications (DAPAN-DIA, NCT06047262) aims to determine whether NLRP3 inhibition with dapansutrile has the potential to not only improve glycaemia but also reduce micro- and macro-vascular risk and complications from diabetes. DAPAN-DIA is a multicenter, pbo-controlled, prospective, randomized, double-blind trial conducted in Switzerland, France, Belgium and Germany. A total of 300 patients with T2D, HbA1c >7.5% and hsCRP>1.5 mg/L are being randomized to either dapansutrile 1000 mg BID or matching PBO tablets for 6 months (2:1 ratio dapansutrile: pbo). The primary endpoint is change from baseline HbA1c. Secondary endpoints include biomarkers associated with diabetic complications, progression of MASLD as well as chronic inflammation (IL-1 β, IL-6 and hsCRP). A subject-assessed QoL questionnaire is also collected. To detect an absolute difference of 0.5% in HbA1c between groups, approximately 300 subjects will be randomized 2:1 ratio to achieve 80% power, assuming a standard deviation of 1.2% in change from baseline in HbA1c at week 26. Results: The trial has launched and currently is enrolling subjects. Conclusions: DAPAN-DIA is the first placebo-controlled, adequately powered, large, multi-center study with an oral NLRP3-specific Inhibitor, dapansutrile. The trial will generate important data on a new clinically relevant dimension in T2D care where consideration at diagnosis of inflammatory parameters are of importance for the transition to T2D-related complications.

Abstract Fugitive emissions of methane (CH4) from force main sewers are of increasing concern. Dosing of additives into force main sewers could be employed to mitigate methane emissions. However, all additives will have embodied greenhouse gas (GHG) emissions. This study examined commonly employed additives in terms of modes of action and potential to mitigate methane generation. Typical dosing strategies reported in the literature for each chemical were compiled and their embodied GHG emissions were summarised from sources in the literature. The net emissions considering mitigated methane generation and embodied GHG emissions were calculated on the basis of typical usage reported in the literature. The results revealed that biofilm shocking strategies and addition of iron have the greatest net reduction in GHG emissions. There is, however, uncertainty associated with the mechanisms by which iron reduces CH4 generation in force mains. Furthermore, future changes in the sourcing of iron may increase its embodied emissions. A qualitative assessment of the impacts of additive use on downstream GHG emissions revealed that they are highly case specific.

Treating healthy but unaesthetic teeth has been a major challenge for a dental practitioner. Maxillary midline diastemas are one such aberration in the smile zone. Although a diastema can be transient in the developing dentition, the management of the diastema in adulthood requires a detailed examination and appropriate care for a successful outcome. Majority of specialty dentists prefer conservative or minimally invasive treatments, such as porcelain laminate veneer (PLV) restorations over full-ceramic crowns for anterior teeth, where esthetics can be extremely concerning. Minimal-thickness laminate veneers provide a satisfactory outcome while preserving the dental structure as a whole. Thus, this clinical report describes a conservative approach of minimal preparation utilizing a restoration to accomplish both esthetic and functional rehabilitation.

The challenges of indexing books on music are centered on its long history, on its international character, on its being a re-creative art, and on the fact that music itself is an abstract and nonv...

Clinical/neuroanatomical localization is one of the neurologist’s most powerful diagnostic tools. We present the case of isolated hypoglossal nerve palsy (IHNP) as the initial presentation of pancreatico-biliary adenocarcinoma. Localization through clinical exam played a critical role in the final diagnosis. A 54 year-old Caucasian female with a remote history of cervical cancer presented with dysarthria and headache. She had headache with fluctuating intensity for three months and new onset speech difficulty. Exam was remarkable for a left cranial nerve twelve palsy and flaccid speech. Detailed neuroimaging was revealing for sclerotic boney lesions and infiltrative bone marrow process at the left clivus and hypoglossal canal, suggestive of malignancy. Further work up definitively diagnosed metastatic panreactico-biliary adenocarcinoma. Her disease progressed despite aggressive chemotherapy. This case illustrates how clinical localization leads to prompt and accurate diagnosis. Isolated hypoglossal nerve palsy is a rare presentation with broad differential. Astute recognition and diagnostic evaluation of examination abnormalities need to be further investigated as some etiology is potentially treatable and reversible. Reported cases include infection, arterial dissections, autoimmune disease, trauma, and local/metastatic neoplasm. Commonly reported neoplasms associated with IHNP are breast, prostate and nasopharyngeal cancer. Pancreatic adenocarcinoma does not typically metastasize to bone, and is a particularly unusual presentation of the disease. There are no previously reported IHNP secondary to pancreatic adenocarcinoma. When the diagnosis is elusive, clinical localization drives the differential and guides further work up. This case re-affirms the importance of the art of localization and its continued relevance even in the modern era of MRI and CT imaging. This is the first reported case of pancreatico-biliary adenocarcinoma causing IHNP.

With extraordinary gains in medical technology comes the increase in medical malpractice litigation. In no area of medicine has the increase in both been more evident than in the surgical management of obesity. The increase in litigation involving bariatric surgery has been attributed to several factors, including an increase in the number of bariatric procedures performed generally (1), inexperience of the operator (2), the inherent risk of these complicated surgical procedures, and the complex nature of the patient population. The consequences of this quantum leap include negative impacts on the cost of professional liability insurance (3,4), the physician credentialing process, and the regulation and discipline of licensed health care practitioners nationwide.